Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development

Zhang, Jiachang; Liu, Wen Li; Tang, Delia C.; Chen, Ling; Wang, Min; Pack, Svetlana D.; Zhuang, Zhengping; Rodgers, Griffin P.

doi:10.1016/s0378-1119(01)00763-6

Cited by 124 publications

(166 citation statements)

References 22 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…These results are consistent with those of a previous report. 8 We confirmed that the OLFM4 mRNA levels determined by quantitative RT-PCR were consistent with the olfactomedin 4 protein levels determined by Western blotting (Fig. 1b).…”

Section: Western Blottingsupporting

confidence: 85%

“…Because OLFM4 is predominantly expressed in bone marrow, small intestine, colon and prostate, 8 we performed immunohistochemical analysis of olfactomedin 4 in non-neoplastic small intestine, colon and prostate (Fig. 2).…”

Section: Immunohistochemical Analysis Of Olfactomedin 4 In Non-neoplamentioning

confidence: 99%

“…5 OLFM4 was originally cloned from human haematopoietic myeloid cells. 8 Although OLFM4 is predominantly expressed in bone marrow, small intestine, colon and prostate, 8 the levels of expression are much lower in normal tissues than in GC tissues. 5 Enhanced olfactomedin 4 expression has been reported in GC by Northern blot analysis 9 and by immunostaining.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Serum olfactomedin 4 (GW112, hGC‐1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients

Oue

Sentani

Noguchi

et al. 2009

Intl Journal of Cancer

104

View full text Add to dashboard Cite

Gastric cancer (GC) is 1 of the most common human cancers. Early detection remains the most promising approach to improving long‐term survival of patients with GC. We previously performed Serial Analysis of Gene Expression (SAGE) on 4 primary GCs and identified several GC‐specific genes including Reg IV. Of these genes, olfactomedin 4 (OLFM4, also known as GW112 or hGC‐1) is a candidate gene for cancer‐specific expression. In this study, we examined the expression of olfactomedin 4 in human GC by immunohistochemistry. We also assessed serum olfactomedin 4 levels in GC patients by enzyme‐linked immunosorbent assay. 94 (56%) of 167 GC cases were positive for olfactomedin 4 by immunostaining. Olfactomedin 4 staining was observed more frequently in stage I/II cases than in stage III/IV cases. The serum olfactomedin 4 concentration in presurgical GC patients (n = 123, mean ± SE, 36.3 ± 3.5 ng/mL) was significantly higher than that in healthy individuals (n = 76, 16.6 ± 1.6 ng/mL). In patients with stage I GC, the sensitivity of serum olfactomedin 4 (25%) and Reg IV (35%) was superior to that of CA19‐9 (5%) or CEA (3%). Furthermore, in patients with stage I GC, the combination of olfactomedin 4 and Reg IV elevated the diagnostic sensitivity to 52%. These results suggest that serum olfactomedin 4 is a useful marker for GC and its measurement alone or in combination with Reg IV has utility in the early detection of GC. © 2009 UICC

show abstract

Section: Western Blottingsupporting

confidence: 85%

Section: Immunohistochemical Analysis Of Olfactomedin 4 In Non-neoplamentioning

confidence: 99%

See 1 more Smart Citation

Serum olfactomedin 4 (GW112, hGC‐1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients

Oue

Sentani

Noguchi

et al. 2009

Intl Journal of Cancer

104

View full text Add to dashboard Cite

show abstract

“…Olfactomedin 4 (OLFM4; also known as hGC-1 and GW112) is a member of olfactomedin domain-containing protein family that has a relatively diverse coil-coil domain in the amino terminus and a well-conserved olfactomedin domain in the carboxyterminus (2). There are at least 13 members of olfactomedin domain-containing proteins in mammals (3).…”

Section: Nf-κb | Nucleotide Oligomerization Domain-1 and -2mentioning

confidence: 99%

Olfactomedin 4 down-regulates innate immunity against Helicobacter pylori infection

Liu

Yan²,

Liu

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

135

152

View full text Add to dashboard Cite

Olfactomedin 4 (OLFM4) is a glycoprotein that has been found to be up-regulated in inflammatory bowel diseases and Helicobacter pylori infected patients. However, its role in biological processes such as inflammation or other immune response is not known. In this study, we generated OLFM4 KO mice to investigate potential role(s) of OLFM4 in gastric mucosal responses to H. pylori infection. H. pylori colonization in the gastric mucosa of OLFM4 KO mice was significantly lower compared with WT littermates. The reduced bacterial load was associated with enhanced infiltration of inflammatory cells in gastric mucosa. Production and expression of proinflammatory cytokines/chemokines such as IL-1β, IL-5, IL-12 p70, and MIP-1α was increased in OLFM4 KO mice compared with infected controls. Furthermore, we found that OLFM4 is a target gene of NF-κB pathway and has a negative feedback effect on NF-κB activation induced by H. pylori infection through a direct association with nucleotide oligomerization domain-1 (NOD1) and -2 (NOD2). Together these observations indicate that OLFM4 exerts considerable influence on the host defense against H. pylori infection acting through NOD1 and NOD2 mediated NF-κB activation and subsequent cytokines and chemokines production, which in turn inhibit host immune response and contribute to persistence of H. pylori colonization.NF-κB | nucleotide oligomerization domain-1 and -2

show abstract

“…The predicted protein structure suggests that CRG-L2 belongs to a family of olfactomedin-related proteins, which includes olfactomedin, myocilin/TIGR, noelin-1, and hGC-1. Olfactomedin-related genes have characteristic tissue-restricted expression patterns suggesting a specialized function for each protein (Richards et al, 1998;Zhang et al, 2002). Based on tissue localization of several olfactomedin family members and the function of TIGR/myocilin, it is possible that olfactomedin-related proteins play an important role in protein-protein interactions within the extracellular matrix (Kulkarni et al, 2000).…”

Section: Crg-l2 Is Upregulated Early During Tumor Development But Is mentioning

confidence: 99%

Identification and characterization of CRG-L2, a new marker for liver tumor development

et al. 2003

View full text Add to dashboard Cite

Liver cancer is very common worldwide and the rates of hepatocellular carcinoma (HCC) have increased by over 70% in the last 2 decades in the US. Late diagnosis, because of the lack of clinical symptoms, and decreased hepatic function, because of underlying hepatic disease, lead to the extremely high mortality rates associated with HCC. Clearly, the identification of markers that are expressed early in the development of HCC and that are easily detected in high-risk patients would aid in early diagnosis and increased survival. We present the cloning and characterization of a novel gene, CRG-L2 (Cancer related gene-Liver 2), which displays high expression in murine and human hepatocellular carcinomas. Using in situ hybridization, we show that CRG-L2 mRNA levels are increased early during the development of liver tumors in C3H/HeJ mice, and that in normal tissues CRG-L2 mRNA is restricted to the murine testis and human placenta. Its restricted expression in normal tissues and unique early upregulation during tumor development make CRG-L2 an excellent candidate as a new clinical marker of HCC.

show abstract

Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development

Cited by 124 publications

References 22 publications

Serum olfactomedin 4 (GW112, hGC‐1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients

Serum olfactomedin 4 (GW112, hGC‐1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients

Olfactomedin 4 down-regulates innate immunity against Helicobacter pylori infection

Identification and characterization of CRG-L2, a new marker for liver tumor development

Contact Info

Product

Resources

About